{"id":27412,"date":"2021-02-14T18:30:01","date_gmt":"2021-02-14T15:30:01","guid":{"rendered":"https:\/\/bgenz.com\/Bio\/product\/human-cancer-antigen-ca15-3-elisa-kit-96-tests\/"},"modified":"2021-02-14T23:36:19","modified_gmt":"2021-02-14T20:36:19","slug":"human-cancer-antigen-ca15-3-elisa-kit-96-tests","status":"publish","type":"product","link":"https:\/\/bgenz.com\/Bio\/product\/human-cancer-antigen-ca15-3-elisa-kit-96-tests\/","title":{"rendered":"Human Cancer Antigen CA15-3 ELISA Kit- 96 Tests"},"content":{"rendered":"<p>Product name<br \/>\nHuman Cancer Antigen CA15-3 ELISA Kit<br \/>\nDetection method<br \/>\nColorimetric<br \/>\nSample type<br \/>\nSerum<br \/>\nAssay type<br \/>\nSandwich (quantitative)<br \/>\nSensitivity<br \/>\n= 5 U\/ml<br \/>\nRange<br \/>\n5 U\/ml &#8211; 240 U\/ml<br \/>\nAssay duration<br \/>\nMultiple steps standard assay<br \/>\nSpecies reactivity<br \/>\nReacts with: Human<br \/>\nProduct overview<br \/>\nab108633 Cancer Antigen CA15-3 Human ELISA Kit is intended for the quantitative determination of the Cancer Antigen CA15-3 concentration in human serum.<\/p>\n<p>Breast cancer is the most common life-threatening malignant lesion in women of many developed countries today, with approximately 180,000 new cases diagnosed every year.<\/p>\n<p>There are a number of tumor markers that can help clinicians to identify and diagnose which breast cancer patients will have aggressive disease and which will have an indolent course. These markers include estrogen and progesterone receptors, DNA ploidy and percent-S phase profile, epidermal growth factor receptor, HER-2\/neu oncogene, p53 tumor suppressor gene, cathepsin D, proliferation markers and CA15-3. CA15-3 is most useful for monitoring patients post-operatively for recurrence, particularly metastatic diseases. 96% of patients with local and systemic recurrence have elevated CA15-3, which can be used to predict recurrence earlier than radiological and clinical criteria. A 25% increase in the serum CA15-3 is associated with progression of carcinoma. A 50% decrease in serum CA15-3 is associated with response to treatment. CA15-3 is more sensitive than CEA in early detection of breast cancer recurrence.<\/p>\n<p>Platform<br \/>\nMicroplate<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Key features and details<br \/>\nSensitivity: 5 U\/ml<br \/>\nRange: 5 U\/ml &#8211; 240 U\/ml<br \/>\nSample type: Serum<br \/>\nDetection method: Colorimetric<br \/>\nAssay type: Sandwich (quantitative)<br \/>\nReacts with: Human<\/p>\n","protected":false},"featured_media":17768,"comment_status":"open","ping_status":"closed","template":"","meta":{"spay_email":""},"_links":{"self":[{"href":"https:\/\/bgenz.com\/Bio\/wp-json\/wp\/v2\/product\/27412"}],"collection":[{"href":"https:\/\/bgenz.com\/Bio\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/bgenz.com\/Bio\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/bgenz.com\/Bio\/wp-json\/wp\/v2\/comments?post=27412"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/bgenz.com\/Bio\/wp-json\/wp\/v2\/media\/17768"}],"wp:attachment":[{"href":"https:\/\/bgenz.com\/Bio\/wp-json\/wp\/v2\/media?parent=27412"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}